發(fā)布時間：2019-05-17 02:57

【摘要】：正克洛維斯腫瘤科學(xué)公司宣布更新PARP1和PARP2強抑制劑rucaparib治療有BRCA基因突變的晚期卵巢癌Ⅱ期臨床試驗資料,證實具有令人非常信服的臨床療效。Ⅱ期臨床ARIEL2試驗研究了rucaparib對204名卵巢癌患者的療效。有BRCA基因突變患者的平均無病情加重存活時間為9.4個月,生物標(biāo)記物陰性者為3.7個月,臨床效果十分顯著。有BRCA基因突變患者82%(32/39)達(dá)到實體瘤治療效果評價標(biāo)準(zhǔn)RECIST和腫瘤標(biāo)記物CA-125測定的有效標(biāo)準(zhǔn),只達(dá)到RECIST有效反應(yīng)者為69%(27/39),疾病控制率為73%;生物標(biāo)記物陰性患者療效較差,只有21%(13/62)達(dá)到實體瘤治療效果評價標(biāo)準(zhǔn)RECIST和腫瘤標(biāo)記
[Abstract]:N Clovis Oncology Science announced the updating of phase II clinical trial data for the treatment of advanced ovarian cancer with BRCA gene mutation with PARP1 and PARP2 strong inhibitor rucaparib. Phase II clinical ARIEL2 trial studied the efficacy of rucaparib in 204 patients with ovarian cancer. The average survival time was 9.4 months in patients with BRCA gene mutation and 3.7 months in patients with negative biomarker. The clinical effect was very significant. 82% (32 鈮，

本文編號：2478749